Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity

Journal of Experimental Medicine

Volumn 174, Issue 1, 1991, Pages 139-149

  Schmidt Wolf, Ingo G H ^a   Negrin, Robert S ^a   Kiem, Hans Peter ^a   Blume, Karl G ^a   Weissman, Irving L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 3;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMAL; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; B-LYMPHOCYTES; BONE MARROW; CELL LINE; COLONY-FORMING UNITS ASSAY; CYTOTOXICITY, IMMUNOLOGIC; HEMATOPOIETIC STEM CELLS; HUMAN; IMMUNOLOGIC DEFICIENCY SYNDROMES; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-2; KILLER CELLS; LYMPHOMA, B-CELL; MALE; MICE; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; NEOPLASM TRANSPLANTATION; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSPLANTATION, HETEROLOGOUS; TUMOR STEM CELL ASSAY;

EID: 0025856106     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.174.1.139     Document Type: Article

References (48)

1. Grimm, E.A., A. Mazumder, H.Z. Zhang, and S.A. Rosenberg. 1982. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp Med. 155:1823.
2. Yagita, M., and E.A. Grimm. (1988) Current understanding of the lymphokine-activated killer cell phenomenon. Prog. Exp Tumor Res. 32:213.
3. Rosenberg, S.A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science (Wash. DC). 233:1318.
4. Ochoa, A.C., G. Gromo, B.J. Alter, P.M. Sondel, and F.H. Bach. 1987. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, β-IL1, interferon-α and -γ. J. Immunol. 138:2728.
5. Whiteside, T.L. 1990. Human tumor-in<rating lymphocytes and their characterization. In Interleukin-2 and Killer Cells in Cancer. E. Lotzova and R.B. Herberman, editors. CRC Press, Inc., Boca Raton, FL. 133-151.
6. Czitrom, A.A., S. Edwards, R.A. Phillips, M.J. Bosma, P. Marrack, and J.W. Kappler. 1985. The function of antigen-presenting cells in mice with severe combined immunodeficiency. J. Immunol. 134:2276.
7. Fulop, G.M., and R.A. Phillips. 1989. Use of scid mice to identify and quantitate lymphoid-restricted stem cells in long-term bone marrow cultures. Blood. 74:1537.
8. Hirayoshi, K., S. Nishikawa, T. Kina, M. Hatanaka, S. Habu, T. Nomura, and Y. Katsura. 1987. Immunoglobulin heavy chain gene diversification in the long-term bone marrow culture of normal mice and mice with severe combined immunodeficiency. Eur. J. Immunol. 17:1051.
9. McCune, J.M., R. Namikawa, H. Kaneshima, L.D. Schultz, M. Lieberman, and I.L. Weissman. 1988. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science (Wash. DC). 241:1632.
10. Bosma, G.C., R.P. Custer, and J.M. Bosma. 1983. A severe combined immunodeficiency mutation in the mouse. Nature (Lond.). 301:527.
11. Bosma, G.C., M.T. Davisson, N.R. Ruetsch, H.O. Sweet, L.D. Shultz, and M.J. Bosma. 1989. The mouse mutation severe combined immunodeficiency (SCID) is on chromosome 16. Immunogenetics. 29:54.
12. Schuler, W., I.J. Weiler, A. Schuler, R.A. Phillips, N. Rosenberg, T.W. Mak, J.F. Kearney, R.P. Perry, and M.J. Bosma. 1986. Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency. Cell. 46:963.
13. Tutt, M.M., W. Schuler, W.A. Kuziel, P.W. Tucker, M. Bennett, M.J. Bosma, and V. Kumar. 1987. T cell receptor genes do not rearrange or express functional transcripts in natural killer cells of SCID mice. J. Immunol. 138:2338.
14. Dorshkind, K., S.B. Pollack, M.J. Bosma, and R.A. Phillips. 1985. Natural killer (NK) cells are present in mice with severe combined immunodeficiency (SCID). J. Immunol. 134:3798.
15. Custer, R.P., G.C. Bosma, and M.J. Bosma. 1985. Severe combined immunodeficiency (SCID) in the mouse. Pathology, reconstitution, neoplasms. Am. f. Pathol. 120:464.
16. McCune, J.M., R. Namikawa, C.-C. Shih, L. Rabin, and H. Kaneshima. 1990. Suppression of HIV infection in AZT-treated SCID-hu mice. Science (Wash. DC). 247:564.
17. Namikawa, R., H. Kaneshima, M. Lieberman, I.L. Weissman, and J.M. McCune. 1988. Infection of the SCID-hu mouse by HIV-1. Science (Wash. DC). 242:1684.
18. Reddy, S., D. Piccione, H. Takita, and R.B. Bankert. 1987. Human lung tumor growth established in the lung and sub- cutaneous tissue of mice with severe combined immunodeficiency. Cancer Res. 47:2456.
19. Dick, J.E. 1989. Establishment of assays for human hematopoietic cells in immune deficient mice. Curr. Top Microbiol. Immunol. 152:219.
20. Kamel-Reid, S., M. Letarte, C. Sirard, M. Doedens, T. Grun-berger, G. Fulop, M.H. Freedman, R.A. Phillips, and J.E. Dick. 1989. A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science (Wash. DC). 246:1597.
21. Charley, M.R., M.T. Tharp.J. Locker, J.S. Deng, J.B. Goslen, T. Mauro, E. Abell, and B. Jegasothy. 1990. Establishment of a human cutaneous T-cell lymphoma in C.B-17 SCID mice. J. Invest. Dermatol. 94:381.
22. Phillips, R.A., M.A.S. Jewett, and B.L. Gallic 1989. Growth of human tumors in immune-deficient SCID mice and nude mice. Curr. Top Microbiol. Immunol. 152:259.
23. Duchosal, M.A., P.J. McConahey, CA. Robinson, and F.J. Dixon. 1990. Transfer of human systemic lupus erythematosus in severe combined immunodeficient (SCID) mice. J. Exp Med. 172:985.
24. Tweeddale, M.E., B. Lim, N. Jamal, J. Robinson, J. Zalcberg, G. Lockwood, M. Minden, and H.A. Messner. 1987. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood. 69:1307.
25. Epstein, A.L., R.J. Marder, J.N. Winter, and R.I. Fox. 1984. Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors. J. Immunol. 133:1028.
26. Negrin, R.S., H.P. Kiem, I.G.H. Schmidt-Wolf, K.G. Blume, and MX. Cleary. 1991. Use of the polymerase chain reaction to monitor the effectiveness of ex-vivo tumor cell purging with antibodies and complement. Blood. 77:654.
27. Schmidt-Wolf, I.G.H., M. Aihara, R.S. Negrin, K.G. Blume, and N.J. Chao. 1989. Lymphokine-activated killer cell activity after cryopreservation. J. Immunol. Methods. 125:185.
28. Cordell, J.L., B. Falini, W.N. Erber, A.K. Ghosh, Z. Abdulaziz, S. MacDonald, K.A.F. Pulford, H. Stein, andD.Y. Mason. 1984. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J. Histochem. Cytochem. 32:219.
29. Alonso, S., A. Minty, Y. Bourlet, and M. Buckingham. 1986. Comparison of three actin-coding sequences in the mouse: evolutionary relationships between the actin genes of warmblooded vertebrates. J. Mol. Evol. 23:11.
30. Stall, A.M., and M.R. Loken. 1984. Allotypic specificities of murine IgD and IgM recognized by monoclonal antibodies. J. Immunol. 132:787.
31. Risser, R., M. Potter, and W.P. Rowe. 1978. Abelson virus-induced lymphomagenesis in mice. J. Exp Med. 148:714.
32. Rosenberg, S.A., M.T. Lotze, L.M. Muul, S. Leitman, A.E. Chang, S.E. Ettinghausen, Y.L. Matory, E. Skibber, E. Shiloni, J.T. Vetto, CA. Seipp, C. Simpson, and CM. Reichert. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313:1485.
33. Papa, M.Z., J.J. Mule, and S.A. Rosenberg. 1986. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonim-munogenic murine tumors of three distinct histological types. Cancer Res. 46:4973.
34. Carter, C.S., S.F. Leitman, H. Cullis, L.M. Muul, K. Nason-Burchenal, S.A. Rosenberg, and H.G. Klein. 1988. Technical aspects of lymphokine-activated killer cell production. J. Clin. Apheresis. 4:113.
35. Teichmann, J.V., W.-D. Ludwig, H. Seibt-Jung, and E. Thiel. 1989. Induction of lymphokine-activated killer cells against human leukemia cells in vitro. Blut. 59:21.
36. Itoh, K., K. Shiiba, Y. Shimizu, R. Suzuki, and K. Kumagai. 1985. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-γ (IFN-γ). J. Immunol. 134:3124.
37. Brunda, M., D. Tarnowski, and V. Davatelis. 1986. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells. Int. J. Cancer. 37:787.
38. Ellis, T.M., R.S. McKenzie, RE. Simms, B.A. Helfrich, and R.I. Fisher. 1989. Induction of human lymphokine-activated killer cells by IFN-α and IFN-γ. J. Immunol. 143:4282.
39. Kaye, J., S. Gillis, S.B. Mizel, E. Shevach, T. Malek, C. Dinarello, L. Lachman, and C. Janeway, Jr. 1984. Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin-1 is required for the expression of receptors for interleukin 2. J. Immunol. 133:1339.
40. Janossy, G. 1987. Bone marrow purging. Immunol. Today. 8:253.
41. Savary, C.A., and E. Lotova. 1990. Down-regulation of human bone marrow cells and their progenitors by IL2-activated lymphocytes. In Interleukin-2 and Killer Cells in Cancer. E. Lot-zova, and R.B. Herberman, editors. CRC Press, Inc., Boca Raton, FL. 89-96.
42. Van den Brink, M.R.M., P.J. Voogt, W.A.F. Marijt, S.A.P. van Luxembourg-Heys, J.J. van Rood, and A. Brand. 1989. Lymphokine-activated killer cells selectively kill tumor cells in the bone marrow without compromising bone marrow stem cell function in vitro. Blood. 74:354.
43. Murphy, M., B. Perussia, and G. Trinchieri. 1988. Effects of recombinant tumor necrosis factor, lymphotoxin, and immune interferon on proliferation and differentiation of enriched hematopoietic precursor cells. Exp. Hematol. 16:131.
44. Rosenberg, S.A. 1986. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In Important Advances in Oncology. V.T. De-Vita, Jr., S. Hellman, and S.A. Rosenberg, editors. J.B. Lip-pincott Company, Philadelphia, PA. 55-91.
45. Topalian, S.L., L.M. Muul, D. Solomon, and S.A. Rosenberg. 1987. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods. 102:127.
46. Lanier, L.L., J.H. Phillips, J. Hackett, Jr., M. Tutt, and V. Kumar. 1986. Natural killer cells: definition of a cell type rather than a function. J. Immunol. 137:2735.
47. Ansell, J.D., and G.J. Bancroft. 1989. The biology of the SCID mutation. Immunol. Today. 10:322.
48. Mosier, D.E., R.J. Golizia, S.M. Baird, and D.B. Wilson. 1988. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (Lond.). 335:256